BATON ROUGE, La. (Louisiana First) — Transcranial magnetic stimulation (TMS) therapy, an alternative treatment for depression and anxiety, gained FDA approval in 2008. NeuroJust, led by CEO Jourdan Generes, offers this treatment for individuals seeking non-medication options for mental health conditions. The widespread use of prescription medications, including antidepressants, became common in America starting in the late 1970s and 1980s, influenced by direct pharmaceutical marketing to the public. TMS therapy, discovered in 1985 using earlier physics principles, presents a non-pharmaceutical approach.
Many of the nation’s largest health plans trust FAIR Health to store, de-identify, aggregate and analyze their claims data. Our processes for handling data contributions meet the industry’s most exacting standards, as demonstrated by our HITRUST, SOC 2 and CMS QE certifications.